Identification and Prevention of Particulates in a Parenteral Solution of a Protein Kinase B Inhibitor

详细信息    查看全文

• 作者：Jenny Dai ; Aktham Aburub
• 关键词：KEY WORDSdegradation products ; mass spectrometry ; particulates ; physical stability ; solubility
• 刊名：AAPS PharmSciTech
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：18
• 期：1
• 页码：202-211
• 全文大小：
• 刊物主题：Pharmacology/Toxicology; Biotechnology; Biochemistry, general; Pharmacy;
• 出版者：Springer US
• ISSN：1530-9932
• 卷排序：18

文摘

The aim of this work was to identify the root cause of particulates in a parenteral solution formulation of a protein kinase B inhibitor (AKT inhibitor) and to devise a formulation fix. While standard potency/purity analyses did not reveal degradation, it was determined that the mass of the particulates corresponds to that of a “dimer-like” degradation product. The dimer-like molecule manifested itself as particulates rather than impurities in standard HPLC analysis. Particulate formation was found to be pH dependent. Consequently, an optimum formulation pH at which the compound has adequate solubility and the rate of particulate formation is slow was identified.